Cargando…
Drug Retention and Safety of Secukinumab in a Real-World Cohort of Ankylosing Spondylitis and Psoriatic Arthritis Patients
Real-life data that support effectiveness of secukinumab (SEC), an interleukin 17A inhibitor, in Poland are few. We aimed to evaluate SEC effectiveness based on drug retention and safety measures reported in electronic medical records (EMRs) of patients with psoriatic arthritis (PsA) and ankylosing...
Autores principales: | Moskal, Mateusz, Krawiec, Piotr, Zaręba, Wojciech, Świerczek, Izabella, Ratusznik, Jakub, Raputa, Wiktor, Zieliński, Maciej, Batko, Krzysztof, Huk, Mikita, Batko, Bogdan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9737777/ https://www.ncbi.nlm.nih.gov/pubmed/36497938 http://dx.doi.org/10.3390/ijerph192315861 |
Ejemplares similares
-
Secukinumab for ankylosing spondylitis and psoriatic arthritis
por: Lubrano, Ennio, et al.
Publicado: (2016) -
Real-world data on secukinumab use for psoriatic arthritis and ankylosing spondylitis
por: Elliott, Ashley, et al.
Publicado: (2019) -
Anatomy of the greater palatine foramen and canal and their clinical significance in relation to the greater palatine artery: a systematic review and meta-analysis
por: Kim, Dong Woon, et al.
Publicado: (2023) -
Association of Secukinumab Treatment With Tuberculosis Reactivation in
Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis
por: Elewski, Boni E., et al.
Publicado: (2021) -
Secukinumab: A Review in Ankylosing Spondylitis
por: Blair, Hannah A.
Publicado: (2019)